DESCRIPTION:

List of positional candidate genes after correcting for multiple testing and controlling the false discovery rate from genome wide association studies (GWAS) retrieved from the NHGRI-EBI Catalog of published genome-wide association studies (http://www.ebi.ac.uk/gwas/). The disease/trait examined in this study, as reported by the authors, was Serum VEGFR2 concentration. The EFO term serum VEGFR2 concentration measurement was annotated to this set after curation by NHGRI-EBI. Intergenic SNPS were mapped to both the upstream and downstream gene. P-value uploaded. This gene set was generated using gwas2gs v. 0.1.8 and the GWAS Catalog v. 1.0.1.

LABEL:

GWAS: serum VEGFR2 concentration measurement

SCORE TYPE:

P-Value

DATE ADDED:

2017-05-02

DATE UPDATED:

2024-04-25

SPECIES:

AUTHORS:

ML Maitland, CF Xu, YC Cheng, E Kistner-Griffin, KA Ryan, TG Karrison, S Das, D Torgerson, ER Gamazon, V Thomeas, MR Levine, PA Wilson, N Bing, Y Liu, LR Cardon, LN Pandite, JR O'Connell, NJ Cox, BD Mitchell, MJ Ratain, AR Shuldiner

TITLE:

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.

JOURNAL:

Clinical cancer research : an official journal of the American Association for Cancer Research Jan 2015, Vol 21, pp. 365-72

ABSTRACT:

VEGF receptor (VEGFR) kinases are important drug targets in oncology that affect function of systemic endothelial cells. To discover genetic markers that affect VEGFR inhibitor pharmacodynamics, we performed a genome-wide association study of serum soluble vascular VEGFR2 concentrations [sVEGFR2], a pharmacodynamic biomarker for VEGFR2 inhibitors. PUBMED: 25411163
Find other GeneSets from this publication